A randomized controlled trial of the effects of low dose zoledronic acid on bone density in osteopenic postmenopausal women

Trial Profile

A randomized controlled trial of the effects of low dose zoledronic acid on bone density in osteopenic postmenopausal women

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms LoDoZe
  • Most Recent Events

    • 11 Sep 2017 Results of 3 years open label extension of the core trial published in the CMAJ: Canadian Medical Association Journal
    • 09 Nov 2011 Results published in the Journal of Clinical Endocrinology and Metabolism.
    • 01 Jul 2009 Additional lead trial centre Health Research Council of New Zealand identified as reported by Australian New Zealand Clinical Trials Registry record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top